Table 2.
Changes in clinical parameters after a three-month course of pemafibrate therapy
| Variables | Baseline | 3 months | P-value |
|---|---|---|---|
| Weight (kg), mean ±SE | 74.7 ±2.6 | 74.4 ±2.6 | 0.261 |
| Body mass index | 28.1 ±0.6 | 28.1 ±0.6 | 0.225 |
| AST (U/l) | 49.1 ±3.7 | 41.6 ±2.8 | 0.028 |
| ALT (U/l) | 63.9 ±3.6 | 41.6 ±3.6 | < 0.001 |
| ALP (U/l) | 301 ±23 | 204 ±18 | < 0.001 |
| γ-GTP (U/l) | 76.8 ±11.8 | 37.5 ±6.3 | < 0.001 |
| Platelet count (× 104/μl) | 25.2 ±0.6 | 27.7 ±0.8 | < 0.001 |
| Estimated GFR (ml/min/1.73 m2) | 77.2 ±2.7 | 76.1 ±2.9 | 0.130 |
| LDL cholesterol (mg/dl) | 98.3 ±4.4 | 93.4 ±4.1 | 0.086 |
| HDL cholesterol (mg/dl) | 51.7 ±2.3 | 54.3 ±2.0 | 0.016 |
| Triglyceride (mg/dl) | 171 ±34 | 115 ±18 | < 0.001 |
| Total bilirubin (mg/dl) | 0.95 ±0.05 | 0.77 ±0.03 | < 0.001 |
| Serum albumin (g/dl) | 4.3 ±0.1 | 4.5 ±0.1 | 0.001 |
| ALBI score | –2.90 ±0.04 | –3.07 ±0.03 | < 0.001 |
| FIB-4 index | 1.51 ±0.16 | 1.47 ±0.12 | 0.500 |
| NAFLD fibrosis score | –2.27 ±0.18 | –2.38 ±0.18 | 0.009 |
SE – standard error, AST – aspartate aminotransferase, ALT – alanine aminotransferase, ALP – alkaline phosphatase, γ-GTP – γ-glutamyl transpeptidase, GFR – glomerular filtration rate, LDL – lowdensity lipoprotein, HDL – highdensity lipoprotein, ALBI – albumin-bilirubin, NAFLD – non-alcoholic fatty liver disease